Verquvo

Chemical Namevericiguat
Dosage FormTablet (oral; 2.5mg, 5mg,10mg)
Drug ClassMiscellaneous
SystemCardiovascular
CompanyMerck & Co.
Approval Year2021

Indication

  • To reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure
  • To reduce the need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%
Last updated on 1/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Verquvo (vericiguat) Prescribing Information2021Merck Sharp and Dohme Corp., Whitehouse Station, NJ